Cargando…

Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine

Drug testing in patient biopsy-derived cells can identify potent treatments for patients suffering from relapsed or refractory hematologic cancers. Here we investigate the use of weakly supervised deep learning on cell morphologies (DML) to complement diagnostic marker-based identification of malign...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heinemann, Tim, Kornauth, Christoph, Severin, Yannik, Vladimer, Gregory I., Pemovska, Tea, Hadzijusufovic, Emir, Agis, Hermine, Krauth, Maria-Theresa, Sperr, Wolfgang R., Valent, Peter, Jäger, Ulrich, Simonitsch-Klupp, Ingrid, Superti-Furga, Giulio, Staber, Philipp B., Snijder, Berend
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Briefs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894727/ https://www.ncbi.nlm.nih.gov/pubmed/36125297 http://dx.doi.org/10.1158/2643-3230.BCD-21-0219

Ejemplares similares

Metabolic drug survey highlights cancer cell dependencies and vulnerabilities
por: Pemovska, Tea, et al.
Publicado: (2021)

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
por: Snijder, Berend, et al.
Publicado: (2017)

Recent advances in combinatorial drug screening and synergy scoring
por: Pemovska, Tea, et al.
Publicado: (2018)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
por: Kornauth, Christoph, et al.
Publicado: (2021)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population
por: Graf, Irene, et al.
Publicado: (2022)

A Conserved Circular Network of Coregulated Lipids Modulates Innate Immune Responses
por: Köberlin, Marielle S., et al.
Publicado: (2015)

Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response
por: Demyanets, Svitlana, et al.
Publicado: (2020)

RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients
por: Berzaczy, Dominik, et al.
Publicado: (2019)

Teduglutide in amyloidosis‐associated intestinal failure
por: Luhn, Clara, et al.
Publicado: (2023)

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience
por: Jeryczynski, G., et al.
Publicado: (2021)

IFITs: Emerging Roles as Key Anti-Viral Proteins
por: Vladimer, Gregory I., et al.
Publicado: (2014)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
por: Jeryczynski, Georg, et al.
Publicado: (2021)

Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy: Breaking a dangerous bond
por: Jeryczynski, Georg, et al.
Publicado: (2022)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
por: Hadzijusufovic, Emir, et al.
Publicado: (2017)

In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells
por: Gamperl, Susanne, et al.
Publicado: (2020)

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2016)

Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2017)

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal()
por: Valent, Peter, et al.
Publicado: (2017)

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
por: Kornauth, Christoph, et al.
Publicado: (2022)

Global survey of the immunomodulatory potential of common drugs
por: Vladimer, Gregory I., et al.
Publicado: (2017)

Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
por: Kropivsek, Klara, et al.
Publicado: (2023)

Multiplexed high-throughput immune cell imaging reveals molecular health-associated phenotypes
por: Severin, Yannik, et al.
Publicado: (2022)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death
por: Dixon, Scott J., et al.
Publicado: (2015)

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas
por: Wagner, Sandro M., et al.
Publicado: (2020)

A time-resolved molecular map of the macrophage response to VSV infection
por: Kandasamy, Richard K, et al.
Publicado: (2016)

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
por: Schalling, Martin, et al.
Publicado: (2017)

Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis
por: Berger, Daniela, et al.
Publicado: (2021)

Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells
por: Gamperl, Susanne, et al.
Publicado: (2019)

Transformed mucosa‐associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction‐based clonality analysis
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
por: Valent, Peter, et al.
Publicado: (2021)

T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?
por: Schreiber, Johanna, et al.
Publicado: (2022)

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
por: Strassl, Irene, et al.
Publicado: (2021)

Current themes in molecular pediatrics: molecular medicine and its applications
por: Superti-Furga, Andrea, et al.
Publicado: (2010)

Cell biology: A key driver of therapeutic innovation
por: Hantschel, Oliver, et al.
Publicado: (2012)

SLC38A9: A lysosomal amino acid transporter at the core of the amino acid-sensing machinery that controls MTORC1
por: Rebsamen, Manuele, et al.
Publicado: (2015)

A structure and evolutionary-based classification of solute carriers
por: Ferrada, Evandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7nv9m4pss51p01h7r8dmvg7frv